Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jul;23(7):2226-2234.
doi: 10.1016/j.jtha.2025.03.003. Epub 2025 Mar 12.

Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial

Affiliations
Randomized Controlled Trial

Perioperative management of direct oral anticoagulants in patients having a high-bleed-risk surgery or neuraxial procedure: the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot randomized trial

James D Douketis et al. J Thromb Haemost. 2025 Jul.

Abstract

Background: There is uncertainty about the perioperative management of patients who are receiving a direct oral anticoagulant (DOAC) and require elective high-bleed-risk surgery, including those who are undergoing a neuraxial or deep peripheral nerve block procedure.

Objectives: The objectives of this pilot trial were to provide preliminary data as to pre-operative residual DOAC levels with different management strategies andro assess the feasibility of a larger trial.

Methods: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE)-2 pilot trial was a proof-of-concept, open-label, randomized controlled trial that assessed the feasibility of comparing perioperative DOAC management using an American Society of Regional Anesthesia (ASRA)-based or PAUSE-based approach in patients with atrial fibrillation who needed an elective high-bleed-risk surgery/procedure and/or any neuraxial anesthesia/procedure.

Results: There were 159 patients enrolled (86 on apixaban, 12 on dabigatran, and 61 on rivaroxaban), of whom 141 had preoperative DOAC-level testing done. The median (IQR) residual DOAC level was 19 (19-24) ng/mL in the ASRA group and 20 (19-24) ng/mL in the PAUSE group (standardized difference = -0.02). The percentage of patients in the ASRA and PAUSE groups with preoperative residual DOAC levels < 30 ng/mL was 95.6% and 94.4%, respectively; the percentage with residual DOAC levels of 30 to 50 ng/mL was 1.4% and 2.8%, respectively, and the percentage with levels > 50 ng/mL was 2.9% and 2.8%, respectively.

Conclusion: In this pilot trial, we found that recruitment of DOAC-treated patients who needed an elective high-bleed-risk surgery or neuraxial procedure was feasible and that preoperative residual DOAC levels appeared similar according to ASRA-based and PAUSE-based management approaches, providing the foundation for a larger trial comparing ASRA- and PAUSE-based perioperative DOAC management.

Keywords: direct oral anticoagulants; neuraxial anesthesia; perioperative medicine; surgery; surgical procedure.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interests J.D.D. discloses receiving funding support from the Canadian Institutes of Health Research and the David Braley Nancy Gordon Chair in Thromboembolic Disease, McMaster University; receiving royalties as a nonemployee contractor for the S. Syed discloses no conflicts of interest.

Publication types

MeSH terms

LinkOut - more resources